Alto Neuroscience, Inc. (NYSE:ANRO) Receives $19.00 Consensus PT from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $19.00.

Several research analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. Chardan Capital initiated coverage on Alto Neuroscience in a research note on Monday, September 29th. They set a “buy” rating and a $15.00 price target on the stock. Robert W. Baird increased their target price on Alto Neuroscience from $10.00 to $16.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, HC Wainwright increased their target price on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 24th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the 2nd quarter valued at $25,000. Ground Swell Capital LLC acquired a new position in Alto Neuroscience during the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC acquired a new position in Alto Neuroscience during the second quarter valued at approximately $33,000. AlphaCore Capital LLC lifted its stake in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in Alto Neuroscience in the first quarter valued at approximately $52,000.

Alto Neuroscience Stock Performance

ANRO stock opened at $11.51 on Friday. The firm has a 50 day simple moving average of $6.80 and a 200 day simple moving average of $4.15. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $15.18. The stock has a market cap of $311.69 million, a P/E ratio of -4.82 and a beta of 2.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.